

**International Consortium for Harmonization of Clinical Laboratory Results**  
**Harmonization Oversight Group / Council Meeting**

**DATE:** 23 March 2021

**TIME:** 13.00 – 14.00 GMT (UK time)

<b>HOG Member</b>	<b>Present</b>	<b>Council Member</b>	<b>Present</b>
Ian Young (chair)	x	Sverre Sandberg (chair, IFCC)	x
Eunice Lee (Vice-Chair)	x	Gye Chol Kwon (KSLM)	
Joseph Passarelli		Gary Myers (AACC)	x
Steve Master		Tony Killeen (CAP)	
Greg Miller	x		
Philippe Gillery (IFCC SD)			
Anja Kessler	x		
Melissa Snyder			
Yeo-Min Yun		<b>Observer</b>	
Amrom Obstfeld		Loretta Doan (AACC)	
Ross Molanaro		Katsuyuki Nakajima (JCCLS)	
YeJin Oh	x		
Huimin Wang			
Susan Copple	x		

**Minutes:**

1) Apologies were received from Joe Passarelli and Philippe Gillery

2) Minutes of the previous meeting (February 17) were approved

3) Membership:

Membership remains as above.

Action: **SS** is currently in discussions with JCCLS

4) Consideration of new measurands

a) Gentamicin – confirmation received that in the DGKL scheme there is good between method agreement apart from negative bias in one Roche method. Similar feedback received from WEQAS. This seems to be a particular issue when gentamicin sulphate (as opposed to the base) is used to spike samples, and is less of an issue in clinical samples. Agreed that current status should be assessed as adequate with a note to this effect. **(IY)**

b) PIVKA-II – EQA information is available from South Korea, and **EL will provide a summary to IY**. Further information has also been provided via Greg M. from David Card (ViaPath UK). IY / Greg M. will discuss the overall position with David Card, and also consider the possibility that he might join the HOG to provide additional input on haematological measurands **(IY)**.

c) Vitamin D – the combined version of the assessment as prepared by SC / IY was approved. **IY** to update the three bodies working in this field with the ICHCLR assessment of the current position.

Various groups involved in standardization activities to be advised of the ICHCLR position and encouraged to collaborate **(IY)**.

d) Tobramycin – text as circulated (YY) agreed and will be uploaded.

e) NT-pro BNP – correspondence received highlights that the current information about NT-pro BNP is out of date as a result of additional available assays. Current information to be removed from measurand list **(Greg M.)**. **IY** to ask Milena Quaglia from LGC to advise on an updated assessment.

f) Tox. gondii – wording as circulated by EL agreed and to be uploaded after minor changes **(IY)**.

g) Fibronectin – wording as circulated by SC agreed and to be uploaded after minor changes **(IY)**. Current status unknown.

## 5) Current and future activities

a) Update from EQALM working group – MUO agreed and in place. Updates will be provided as required on an ongoing basis.

b) Links with clinical societies – Draft information for sharing with clinical societies circulated. Any comments to be provided to IY in next two weeks along with suggestions for key societies **(All)**. **IY and SS** to agree final version and distribution will then begin.

c) Awareness of ICHCLR role and resources - Annual / biannual newsletter to be prepared for circulation to key stakeholders and dissemination via IFCC news / AACC news etc **(IY)**

d) Call for programs of work to harmonize high priority measurands

Meeting with IFCC SD to be held in next two weeks and update will be provided **(IY)**

e) Review of listed measurands – a light touch approach will be taken to review of existing measurands. For new measurands the date of upload will be included on the database, and a review date (3 years). A check will be made with an EQA scheme using commutable samples, or in the absence of a published scheme for published data. A more in depth reassessment will be taken only if status appears to have changed or in the event of other relevant correspondence being received. **(IY)**

6) Update on measurand list –

a) current assignments:

Urinary creatinine (AK)

Urinary calcium (AK)

Apo A1 (Gary M)

Apo B (Gary M)

Lp(a) (Gary M)

Osmolality (blood / urine) (Greg M)

Quinidine (JP)

Hepatitis A Ab IgG (MS)

Hepatitis A Ab IgM (MS)

Hepatitis A Ab (total) (MS)

Benzodiazepines (RM)

CK19F (SM)

Methemoglobin (Tony – IY to check with WEQAS re any available data)

Ammonia (IY)

Acetaminophen (SC)

Salicylate (SC)

T.Pallidum (EL)

b) unallocated

51      Pre Albumin  
          (Transthyretin)

67      Haptoglobin